Background: Tranexamic acid decreases total blood loss after total hip arthroplasty (THA). Total blood loss is the sum of external bleeding and bleeding into tissues, i.e., haematomas. Haematomas may cause acute or even chronic postoperative pain. Hypothesis: Tranexamic acid decreases haematomas, thereby diminishing postoperative pain after THA. Methods: In a retrospective matched case-control study, patients receiving tranexamic acid (15 mg/kg, before the incision and again at skin closure) were compared to controls not given tranexamic acid. Matching was on sex, surgeon, and peri-operative analgesics (ketamine, ketoprofen, pregabalin, and nefopam). Standardised protocols were used for anaesthesia, analgesia, and blood sparing. Haematoma volume was computed as the difference between total blood loss (estimated from the erythrocyte counts on days -1 and +5) and measured external blood loss. Patients were monitored from D0 to D7 then interviewed by telephone on D30, D90, and D180. To detect a 30%-decrease in the morphine dose at H24 (criterion 1) and D7 (criterion 2) and a 20% decrease in haematoma volume on D5 (criterion 3), the required numbers of patients were 90, 90, and 77, respectively; therefore, 95 patients were included. * Corresponding author. Results: Tranexamic acid decreased haematoma volume by 30% (351 ± 254 mL versus 247 ± 189 mL erythrocytes, P = 0.002), had no effect on morphine consumption at H24 (12 ± 11 mg versus 14 ± 12 mg, P = 0.346), increased morphine consumption on D7 (26 ± 24 mg versus 35 ± 36 mg, P = 0.029), and had no effect on long-term pain. Discussion: After THA, tranexamic acid decreases haematoma volume without improving analgesia. Level of evidence: 3 (case-control study).
Introduction
Surgery is followed by acute and chronic pain. Although about 100 000 patients undergo primary THA each year in France, the contribution of haematomas to acute and chronic postoperative pain is unclear. Haematomas may cause pain via local compression and/or via the inflammatory process needed to achieve their resorption.
Tranexamic acid is an antifibrinolytic agent. When given intravenously during surgery, tranexamic acid diminishes total blood loss and blood transfusion requirements after THA, apparently without increasing the risk of thrombosis [1, 2] . Total blood loss is the sum of external bleeding (surgical field and drains) and hidden bleeding (haematomas and blood infiltrating the tissues around the surgical site). No studies have evaluated the effect of tranexamic acid on haematoma volume after THA.
Our objective in this study was to evaluate whether tranexamic acid decreased postoperative haematoma volume after THA and whether this effect, if demonstrated, was associated with decreased pain.
Methods Patients
We conducted a retrospective single-centre case-control study using a database including consecutive adults who underwent primary THA between January 2007 and May 2011 in a teaching hospital department. Exclusion criteria were absence of data on the main evaluation criteria and/or matching criteria; contra-indication to tranexamic acid (thromboembolic event in the past 6 months, thrombophilia, coronary angioplasty, cerebrovascular event, peripheral arterial disease stage III-IV, creatinine clearance less than 30 mL/min, or epilepsy); contra-indication to paracetamol (allergy or porphyria); inability of the patient to self-assess pain intensity on a numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable); inability of the patient to use a patient-controlled analgesia device; and preoperative pain requiring more than 20 mg morphine equivalent per day.
Anaesthesia
Premedication was with 0.5 mg alprazolam before 2009 and 50 to 150 mg pregabalin (depending on renal function and age) thereafter.
Patients were monitored for ECG, blood pressure, oxygen saturation, neuromuscular blockade, blood gas values, and oesophageal temperature. A forced-air warming blanket was used to maintain body temperature. All THA procedures were performed under general anaesthesia induced with 0.2-0.4 g/kg sufentanil, 2-3 mg/kg propofol, and 0.5 mgkg atracurium. Orotracheal intubation was then performed and anaesthesia maintained with inhaled sevoflurane and nitrous oxide. Repeat injections of sufentanil or atracurium and the use of intravenous ephedrine, atropine, and fluids were at the discretion of the anaesthesiologist in charge of the patient.
Operative technique
All patients were in the lateral decubitus position. Various surgical approaches and prosthesis types (cemented or uncemented) were used. All THA procedures were performed by, or under direct supervision by, an orthopaedic surgeon fellow or university-hospital orthopaedic surgeon.
Analgesia
A 0.5 mg/kg ketamine bolus injected shortly before the incision was followed by a continuous infusion (2 g/kg/min) for 24 hours [3, 4] .
At the end of the THA procedure, the patient was given an injection of paracetamol 1 g and ketoprofen 50 mg (in the absence of contra-indications: creatinine clearance < 30 mL/min, history of gastro-duodenal ulcer, allergy, or thrombocytopenia < 100 000/mm 3 ). Paracetamol therapy was continued throughout the hospital stay (3-4 g per day) and ketoprofen therapy for 48 hours (200 mg per day). Nefopam was used also (120 mg per day for 48 hours) in 2008 and pregabalin bid for five days thereafter.
In the post-anaesthesia care unit, morphine titration was performed in patients with NRS scores greater than 3 (2-3 mg IV every five minutes until the NRS fell below 4 or side effects developed). All patients then received patientcontrolled analgesia with morphine-droperidol (1-mg bolus, 7-minute refractory period, maximal dose of 20 mg/4 hours) for at least 24 hours, followed by oral morphine sulphate (20 mg if NRS score > 3).
Episodes of nausea or vomiting were managed with 4 mg of ondansetron.
Pain intensity was evaluated at the bedside during the hospital stay then during telephone interviews (D30, D90, and D180) using a standardised questionnaire [4] . In patients not available for interview on D180, the D90 data were used instead of the D180 data in the analysis.
Blood-sparing strategy
We used a previously described strategy [5, 6] . Oral iron and folic acid supplements were given preoperatively, as well as two to three human recombinant erythropoietin injections in patients whose haematocrit was less than 39% at the preanaesthesia visit.
The decision to use tranexamic acid (Exacyl ® , SanofiAventis France, Paris, France) was at the discretion of the anaesthesiologist in charge of the patient. Two injections (15 mg/kg over 20 minutes) were given at the beginning and at the end of anaesthesia.
Intra-operative cell salvage was very rarely used. Starting in 2010, intravenous iron was given postoperatively in patients whose haematocrit was less than 33%. Homologous red-blood-cell packs were transfused if the haematocrit fell below 21%; a higher cut-off of 30% was used when clinical tolerance of the anaemia was poor and in patients with coronary artery disease or other types of heart disease.
Blood cell counts and serum assays of electrolytes and creatinine were obtained on D-1, D1, and D5.
Thromboprophylaxis involved a daily fondaparinux injection (2.5 mg) starting 8 hours after surgery. A daily enoxaparin injection (4000 IU) was used instead in patients with a creatinine clearance less than 30 mL/min, age above 80 years, or body weight less than 50 kg.
Statistical analysis
The main evaluation criteria were haematoma volume (taken as a surrogate for blood losses into tissues) and morphine doses at H24 and D7. Haematoma volume was estimated in millilitres of red blood cells by subtracting external blood loss from total blood loss [7] , as shown in Fig. 1 .
In the 736 evaluable patients, mean total blood loss was 535 ± 283 mL. Assuming a haematoma volume equal to 50% of total blood loss (267 ± 141 mL), 77 patients were needed in each group to detect a 20% decrease in haematoma volume with ␣ set at 0.05 and ␤ at 0.10.
The morphine doses administered to the patients were converted to intravenous equivalents (30 mg orally = 20 mg sub-cutaneously = 10 mg intravenously). Mean morphine doses used in our department were 10 ± 10 mg on H24 and 20 ± 20 mg on D7 (in 160 patients, from November 2007 to August 2009, given paracetamol, ketoprofen, ketamine, and pregabalin). To detect a 30% decrease in morphine doses at H24 and D7, 90 patients were needed in each group with ␣ set at 0.05 and ␤ at 0.10.
We decided to include 95 patients in each group.
Matching
Each control not given tranexamic acid was matched to a case given tranexamic acid on six criteria: sex, surgeon, nefopam, ketoprofen, pregabalin, and ketamine. All patients received paracetamol. One of us (MC) matched the patients using a database of 736 anonymised patients containing only information on the matching criteria. When several controls were identified for a single patient, the control having the smallest identification number was chosen.
Expression of data
Continuous quantitative data were described as mean ± SD and other data as number (%). Quantitative variables were compared using Student's t test for paired data and qualitative variables using Fisher's test. Values of P less than 0.05 were considered significant. The statistical analyses were performed using PASW Statistics 18 software (SPSS Inc., Chicago, IL, USA).
Results

Patients and procedures
In each group of 95 patients (55 women and 40 men), 89 patients received ketoprofen, 87 ketamine, 25 nefopam, and 37 pregabalin.
No statistically significant baseline differences were found between the two groups ( Table 1) .
During surgery (Table 2) , the cases received smaller amounts of crystalloids and vasoactive agents than did the controls. No significant differences were found between the two groups for the intra-operative surgical data. Although the operating time was shorter in the cases than in the controls, the difference failed to reach statistical significance.
Blood losses
In the cases, total blood loss was lower by 28% (P < 0.001) and haematoma volume by 30% (from 351 ± 254 to 247 ± 189 mL red blood cells, P = 0.002) compared to the controls, and the decreases were apparent as early as D1 (Table 3) .
The proportion of patients with clinical haematomas was not significantly different between the two groups. Intraoperative cell salvage was used in two patients, both in the control group. A case with spondylo-epiphyseal dysplasia underwent drainage of a haematoma on D14; the fluid was sterile, no neurovascular complications were recorded, and no blood transfusion was required. A patient in the control group experienced deep vein thrombosis.
The amount of morphine used by H24 was not significantly different between the two groups (12 ± 11 mg in the controls and 14 ± 12 mg in the cases, P = 0.346) ( Table 4) . Morphine consumption was lower in the controls than in the cases at H48 and on D7 (26 ± 24 mg versus 35 ± 36 mg, P = 0.029).
The follow-up data showed no significant between group differences in hip pain at rest, hip pain while walking, or functional recovery.
Discussion
In this retrospective case-control study, tranexamic acid administration to patients undergoing THA decreased haematoma volume by 30% but had no effect on early or delayed postoperative pain intensity.
The retrospective design is a limitation of our study. However, the individual matching of cases and controls limited the risk of bias regarding the main factors known to influence Figure 1 Method used to estimate haematoma volume. Obesity was defined as a body mass index (weight in kg/height in m squares) greater than 30 kg/m 2 . Based on a discussion between the physicians and surgeons in charge of the patients, the mean amount of blood lost by aspiration and in swabs was estimated at 200 mL. Blood lost through drains was defined as undiluted blood before D1 (at 8:00 am) and blood diluted by half thereafter (based on the dilutions of 0.84 before D1 and 0.58 after D1 reported after knee arthroplasty [7] ). mL: millilitres.
postoperative pain and bleeding. Thus, paracetamol [8] , ketoprofen [8] , ketamine [4] , pregabalin [9] , and nefopam (used alone) [10] have been reported to decrease morphine consumption after THA. Female gender was associated with an increased risk of acute postoperative pain [11] . The surgeon clearly has a major influence on both pain and total blood loss. Control of this last variable is better in a case-control study than with a randomised design, which never involves stratification on surgeons. An effect of nonsteroidal anti-inflammatory drugs on haemostasis has been documented after tonsillectomy [12] but remains controversial in orthopaedic surgery. Finally, matching allowed us to obtain two groups exhibiting similar pre-and intra-operative characteristics.
Our study confirms that tranexamic acid decreases total blood loss during THA. Homologous blood transfusion is rarely used in THA (8% versus 3%) and, therefore, the statistical power for detecting a difference in this variable is low.
The benefits of tranexamic acid seem to start early, during the surgical procedure, since the need for vasoactive agents and intravenous volume repletion are diminished. Finally, the lower serum creatinine level on D5 in the tranexamicacid group may reflect greater stability of blood volume. The use of tranexamic acid may decrease the operating time ( Table 2 , p = 0.053). Easier haemostasis and better visibility of the operative field may explain this finding.
We found that tranexamic acid therapy was associated with a 30% decrease in haematoma volume, as early as D1 and until D5. Nevertheless, the proportion of patients with clinical haematomas was not significantly diminished (27% versus 16%, P = 0.108), a fact that probably reflects inadequate statistical power. The use of postoperative drainage may have decreased the overall rate of haematomas, despite controversy about the efficacy of this measure [13] . Therefore, tranexamic acid therapy may be particularly helpful when drainage is not used. ASA: American Society of Anesthesiologists score; OA, osteoarthritis; NRS, numeric rating scale (used to score pain in the operated hip). The data are mean ± SD or n (%). a Missing for six patients in each group. b Tramadol, dextropropoxyphene, or morphine < 20 mg per day; missing for one case and two controls.
Although haematoma size decreased, no improvement in postoperative analgesia was seen in the tranexamic acid group compared to the controls. Most of the patients received multimodal analgesia with three to four non-opioid analgesics. This fact explains the low levels of morphine consumption. However, the study was powered to detect a 30%-decrease in morphine consumption at H24 in this situation. The absence of an effect on pain cannot be ascribed to the use of an inadequate dosage of tranexamic acid: we used the same dosage as in most of the previously reported protocols [2] .
Our findings after THA are similar to those reported previously after knee arthroplasty [7] . They suggest that, after THA, haematomas contribute only a small proportion of total postoperative pain. Alternatively, the decrease in haematoma volume achieved by using tranexamic acid may have been too small to significantly affect pain (104 mL of red blood cells is equivalent to 300-400 mL of blood based on the haematocrit). The number of patients with diabetes or antidepressant therapy was higher in the control group than in the case group. However, a confounding effect of these two factors is unlikely, as the differences were not significant, the prevalence was less than 15%, and diabetes can induce either hyperalgesia or hypoesthesia. The increased morphine consumption noted on D7 in the cases may be ascribable to hyperalgesia induced by tranexamic acid, as application of tranexamic acid to the spinal cord has been reported to induce hyperalgesia in an anaesthetised rat model [14] . Unfortunately, this effect was not sought in our patients. The small increase in morphine consumption in the cases (9 mg) had no impact on pain scores, morphine-related side effects, functional recovery, or delayed pain after THA. Therefore, this effect does not challenge the use of tranexamic acid, whose beneficial effects in terms of blood sparing far outweigh the small increase in morphine consumption on D7.
Intra-operative administration of tranexamic acid during THA decreases total blood loss and haematoma volume but has no effect on pain in the early postoperative period or after 6 months.
